News

The application for Gilotrif is currently under review for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR)

They found that an FDA approved drug for non-small cell lung cancer called ceritinib has anti-cancer activity against previously unknown targets. Their results were published today in the

The US-based pharma giant said that it may consider a full or partial separation of Pfizer Consumer Healthcare either through a spin-off or other transaction apart from the

Top-line data, based on the 16-week primary endpoint, is anticipated early in the first quarter of 2018. Subjects were enrolled in 30 renal centres across the USA. A

The BTD designation granted by the US Food and Drug Administration (FDA) is indicated for the treatment of metastatic NSCLC patients who are growth factor receptor (EGFR) mutation-positive. It

The milestone is due to the successful completion of a screening campaign using Evotec's induced pluripotent stem cell ("iPSC")-based screening platform. This milestone has been achieved under an

The company has recruited first patient in the trial of NanoPac sterile suspension in patients with ovarian cancer. The trial will assess NanoPac’s safety and efficacy after IP

These funds will enable clinical advancement of PAN-90806, a small molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop for the treatment of neovascular eye diseases. The additional financing,

Synthon’s three-times-a-week glatiramer acetate is a therapeutically equivalent version of the originator medicine Copaxone®* 40mg.  Synthon received regulatory clearance in all 27 EU/EEA member states involved in the